

Pediatric omeprazole suspension

Proven six-month stability in a banana-flavored suspension

Commercial omeprazole capsules and tablets aren't suitable for pediatric use. The drug itself is highly susceptible to breakdown in a liquid dosage form, making it inadequate over a short period of time. **There is a need for a compounded oral liquid alternative with extended stability.**


The solution

PCCA SuspendIt® is an all-in-one compounding base that enables the preparation of an age-appropriate omeprazole oral suspension, providing:

- customizable dosing from 2 mg/mL up to 10 mg/mL
- palatable banana flavoring for improved taste and compliance
- extended stability and compatibility with omeprazole
- continued drug effectiveness over time due to lack of drug breakdown

Proven stability

Validated 6-month stability study using Ultra-High Performance Liquid Chromatograph (UHPLC) analysis tested two omeprazole suspensions (2 mg/mL and 10 mg/mL) and demonstrated a six-month beyond-use date at refrigerated temperature.



- **Potency (strength) maintained:**
92.19%–99.30% (2 mg/mL)
96.37%–103.45% (10 mg/mL)
- **Consistent color and flavor**
- **Stable pH and density**
- **Six-month beyond-use date**

Benefits



For caregivers and patients

- Less visits to the pharmacy and significant cost savings over time
- Safety and assurance that the prescription will deliver a consistent dose of drug from beginning to end



For hospital and community pharmacists

- Extended stability enables preparation of larger batches, reducing the need for frequent compounding
- Validated stability data ensures reliable, high-quality compounding with confidence



For physicians

- Peer-reviewed, validated stability study presented at the renowned EuPFI pediatric conference
- Age- and weight-specific dosing suspensions with unique properties ensuring accurate, uniform delivery with every dose

Read the scientific poster: Shan, A., Ip, K., Carvalho, M. and Banov, D. (2018) Physicochemical stability of omeprazole 2 mg/mL and 10 mg/mL oral suspensions in SuspendIt®, presented at the 10th European Paediatric Formulation Initiative (EuPFI) conference, poster presentation. London, UK: 12-13 September. Available [here](#) or scan the QR code.

For more information about the study contact: PCCAScience@pccarx.com.

